Juvenile-onset systemic lupus erythematosus (jSLE) – Pathophysiological concepts and treatment options. Issue 4 (August 2017)

• Record Type: Journal Article
• Authors: Hedrich, Christian M.; Smith, Eve M.D.; Beresford, Michael W.
• Is Part Of: Best practice & research. Volume 31:Issue 4(2017:Aug.)
• Page Start: 488
• Page End: 504
• Publication Date: 2017-08
• Subjects: Juvenile-onset systemic lupus erythematosus -- Early-onset SLE -- SLE -- Tissue damage -- Autoinflammation -- Autoimmune -- Inflammation -- Treatment -- Individualised -- Target-directed; Rheumatology -- Periodicals; Rheumatic Diseases -- Periodicals; Reumatologie; 616.723005
• DOI: 10.1016/j.berh.2018.02.001
• Languages: English
• ISSNs: 1521-6942

Abstract

Abstract: The systemic autoimmune/inflammatory condition systemic lupus erythematosus (SLE) manifests before the age of 16 years in 10–20% of all cases. Clinical courses are more severe, and organ complications are more common in patients with juvenile SLE. Varying gender distribution in different age groups and increasing severity with younger age and the presence of monogenic disease in early childhood indicate distinct differences in the pathophysiology of juvenile versus adult-onset SLE. Regardless of these differences, classification criteria and treatment options are identical. In this article, we discuss age-specific pathomechanisms of juvenile-onset SLE, which are currently available and as future treatment options, and propose reclassification of different forms of SLE along the inflammatory spectrum from autoinflammation to autoimmunity.